Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Protara Therapeutics, Inc. Chief Commercial Officer William Conkling reported a routine tax-related share disposition. On June 2, 2026, 6,008 shares of common stock were withheld by the company at $4.34 per share to cover income tax obligations from the vesting of Restricted Stock Unit Awards granted on June 2, 2025. After this withholding, Conkling directly holds 69,992 shares of Protara common stock. This transaction was not an open-market purchase or sale, but an administrative step tied to equity compensation.
Protara Therapeutics (TARA) has filed a prospectus supplement to sell up to $100,000,000 of common stock through an at-the-market sales agreement with TD Securities (USA) LLC (TD Cowen). Shares may be sold from time to time under the Sales Agreement, which permits sales on Nasdaq or by other methods permitted by law.
This offering is part of a $300,000,000 shelf registration. The prospectus supplement states last reported sale price of $5.27 per share on May 11, 2026 and uses proceeds to fund clinical development of TARA-002, IV Choline Chloride and other programs. The Sales Agreement allows TD Cowen to act as agent or principal, with compensation up to 3.0% of gross proceeds, and contains customary indemnification provisions.
Janus Henderson Group plc reports beneficial ownership of 5,207,011 shares of Protara Therapeutics, Inc. common stock, representing 9.6% of the class. The holdings are reported on behalf of multiple investment advisers that exercise shared voting and dispositive power for managed portfolios.
The filing notes that the Managed Portfolios generally exercise investment and voting discretion but do not have rights to receive dividends or sale proceeds; the Janus Henderson Biotech Innovation Master Fund Ltd. holds the right to receive dividends or proceeds for more than 5% of the class. The amendment is signed on 5/15/2026.
Protara Therapeutics, Inc. has registered a shelf to offer up to $300,000,000 of common stock, preferred stock, debt securities and/or warrants.
The prospectus states the registration includes $110,914,137.87 of unsold securities from a prior registration and that specific terms and proceeds treatment will be set forth in future prospectus supplements. The company notes its Nasdaq symbol is TARA and that its common stock last traded at $5.27 per share on May 11, 2026. The filing reiterates that proceeds will be used for general corporate purposes, including research and development, clinical trials and working capital.
Protara Therapeutics reported a wider net loss for the three months ended March 31, 2026 as it accelerated investment in its pipeline. Net loss was $17.8 million versus $11.9 million a year earlier, driven by higher research and development spending of $13.6 million and general and administrative costs of $6.1 million.
The company ended the quarter with $177.4 million in unrestricted cash, cash equivalents and marketable debt securities and believes this will fund operations for at least 12 months. Protara advanced multiple programs, including TARA-002 for non-muscle invasive bladder cancer with promising complete response rates, TARA-002 for pediatric lymphatic malformations with interim clinical success in STARBORN-1, and initiated the registrational THRIVE-3 Phase 3 trial for IV Choline Chloride in long-term parenteral support patients.
Protara Therapeutics reported a larger net loss as it advances its pipeline. For the quarter ended March 31, 2026, the company recorded a net loss of $17.8 million, compared with $11.9 million a year earlier, driven by higher research and development and general and administrative expenses.
Research and development spending rose to $13.6 million, while general and administrative costs were $6.1 million. Protara ended the quarter with cash, cash equivalents and investments of approximately $177 million, which it expects will fund operations into 2028.
Clinically, the company plans to submit a Biologics License Application for TARA‑002 in lymphatic malformations in the second half of 2027, and aims to complete enrollment of the BCG‑unresponsive registrational cohort of the ADVANCED‑2 bladder cancer trial and start the ADVANCED‑3 registrational trial in BCG‑naïve patients in the second half of 2026. It also expects multiple data readouts in 2026, including interim TARA‑002 data and interim THRIVE‑3 IV Choline Chloride results.
Protara Therapeutics, Inc. is asking stockholders to vote on seven proposals at its virtual 2026 annual meeting on June 12, 2026. Items include electing three Class III directors, ratifying Ernst & Young LLP as auditor, and advisory votes on executive pay and its frequency.
Stockholders will also consider an amendment to the 2024 Equity Incentive Plan and two charter amendments: one to increase authorized common shares from 100,000,000 to 200,000,000, and another to add officer exculpation as permitted by Delaware law. A record 55,060,500 common shares are entitled to vote as of April 15, 2026.
Protara Therapeutics reports that BlackRock, Inc. beneficially owns 3,387,459 shares of Common Stock, representing 6.3% of the class as of 03/31/2026. The filing states BlackRock has sole voting power for 3,347,945 shares and sole dispositive power for 3,387,459 shares. The schedule notes various persons may have rights to dividends or sale proceeds and is signed by a BlackRock Managing Director on 04/27/2026.